Literature DB >> 17373356

Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria.

Anuj K Gupta1, D S Chauhan, K Srivastava, R Das, Shweta Batra, Mayank Mittal, Pooja Goswami, Neelja Singhal, V D Sharma, K Venkatesan, S E Hasnain, V M Katoch.   

Abstract

Multidrug resistance has been posing an increasing problem in the treatment of tuberculosis. Mutations in the genomic targets of drugs have been identified as the major mechanism behind this resistance. However, high degree of resistance in some isolates towards major drugs like rifampicin, isoniazid, ethambutol and streptomycin can not be explained solely on the basis of mutations. Besides this, certain other mechanisms like efflux pumps have also been considered as alternative mechanisms in the drug resistant isolates where there is no mutation and these mechanisms are specially important for drug resistance in non-tuberculous mycobacteria (NTM). In this study, we have estimated efflux pump mediated drug resistance in different mycobacterial species with the help of efflux pump inhibitors. All major anti-tuberculous drugs have been shown to be extruded by efflux pumps and the degree to which these drugs are extruded, vary in different mycobacterial species and isolates. The correlation of this resistance with functional activity of two major efflux pump genes pstB and Rv1258c was also assessed by reverse transcription PCR. Besides the significant role of these pumps observed, other efflux pumps, present in mycobacteria, may also be involved in drug resistance and need to be investigated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17373356

Source DB:  PubMed          Journal:  J Commun Dis        ISSN: 0019-5138


  26 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

Review 2.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 3.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

4.  Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.

Authors:  Santiago Ramón-García; Carlos Martín; Charles J Thompson; José A Aínsa
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 5.  Do Shoot the Messenger: PASTA Kinases as Virulence Determinants and Antibiotic Targets.

Authors:  Daniel A Pensinger; Adam J Schaenzer; John-Demian Sauer
Journal:  Trends Microbiol       Date:  2017-07-19       Impact factor: 17.079

Review 6.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

7.  Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

Authors:  Nicholas D Walter; Gregory M Dolganov; Benjamin J Garcia; William Worodria; Alfred Andama; Emmanuel Musisi; Irene Ayakaka; Tran T Van; Martin I Voskuil; Bouke C de Jong; Rebecca M Davidson; Tasha E Fingerlin; Katerina Kechris; Claire Palmer; Payam Nahid; Charles L Daley; Mark Geraci; Laurence Huang; Adithya Cattamanchi; Michael Strong; Gary K Schoolnik; John Lucian Davis
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

8.  Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.

Authors:  John D Szumowski; Kristin N Adams; Paul H Edelstein; Lalita Ramakrishnan
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

9.  Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.

Authors:  Jansy Sarathy; Véronique Dartois; Thomas Dick; Martin Gengenbacher
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.

Authors:  Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.